Tuesday 3rd April 2018
|Text too small?|
Volpara Health Technologies, the Kiwi digital health firm listed on the ASX, said it exceeded its goal of lifting annual recurring revenue 200 percent for the financial year ended March 31.
Wellington-based Volpara, which focuses on early detection of breast cancer using artificial intelligence, said in a statement to the Australian stock exchange that its ARR now stands at $3.6 million. That's compared to $1.1 million at the end of FY2017, an increase of 223 percent.
ARR is the normalised amount of cash reasonably expected to be booked for the next 12 months based on the contracts signed previously, and assuming installation upon order, according to Volpara. Its total contract value - or the value of contracts signed in the specified period - exceeded $11.2 million, up 173 percent on the prior year's $4.1 million.
The company also said that approximately 3.2 percent of all women screened in the US are now contracted to Volpara’s software (approximately 1.27 million women), compared to the target for the year of 3 percent.
"We are just scratching the surface of the market in the US, but the signs are very encouraging," said Volpara chief executive Ralph Highnam.
The ASX-listed shares rose 5.6 percent to 76 Australian cents.
No comments yet
MARKET CLOSE: NZ shares gain; a2 hits new record, F&P climbs on patent deal
NZ dollar eases against Aussie on strong jobs data
KiwiSaver funds face unrealised capital gains tax on NZ and Aussie shares
Planning changes need to speed renewables development - Meridian
A guide to the Tax Working Group's 'other' recommendations
MYOB adds 57% more subscribers in 2018 but total online customers still lag Xero's
Investors fear chilling effect as former IRD boss opposes capital gains proposals
Stuff 1H earnings slide but Nine still optimistic of finding buyer
NZ Post achieves first-half revenue growth for the first time since 2015
TeamTalk affirms annual earnings guidance as rising costs dent first-half profit